Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia

Feng Niu, Jialing Wen, Xinhui Fu, Chujun Li, Rongsong Zhao, Shan Wu, Hao Yu, Xianglin Liu, Xia Zhao, Side Liu, Xinying Wang, Jianping Wang, Hongzhi Zou

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Although the incidence of colorectal cancer is steadily increasing, screening for colorectal cancer with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. Syndecan-2 (SDC2) is frequently methylated in colorectal cancer. However, the value of a stool test of methylated SDC2 for the detection of colorectal cancer is unknown. Methods: Methylation status of SDC2 was tested in cell lines and 398 colorectal tissue samples and further evaluated with 497 stool samples, including 196 from colorectal cancer patients, 122 from adenoma patients, and 179 from normal individuals, using real-Time methylation-specific PCR. The impacts of one quantitative partial stool sampling device and 17 potentially interfering substances on the performance of fecal methylated SDC2 were also analyzed. SDC2 expression was also measured. Results: SDC2 methylation level was higher in 96.8% (120/ 124) of colorectal cancer tissues compared with paired adjacent normal epithelia. Stool test of methylated SDC2 detected 81.1% (159/196) of colorectal cancer and 58.2% (71/122) of adenomas at a specificity of 93.3% (167/179). No significant difference was found between partial and whole stool collection on colorectal cancer detection (P > 0.05, R2 = 0.80). Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2. SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia. Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms. Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.

Original languageEnglish (US)
Pages (from-to)1411-1419
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number9
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Syndecan-2
Colorectal Neoplasms
DNA
Neoplasms
Methylation
Adenoma
Epithelium
Berberine

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia. / Niu, Feng; Wen, Jialing; Fu, Xinhui; Li, Chujun; Zhao, Rongsong; Wu, Shan; Yu, Hao; Liu, Xianglin; Zhao, Xia; Liu, Side; Wang, Xinying; Wang, Jianping; Zou, Hongzhi.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 9, 01.09.2017, p. 1411-1419.

Research output: Contribution to journalArticle

Niu, F, Wen, J, Fu, X, Li, C, Zhao, R, Wu, S, Yu, H, Liu, X, Zhao, X, Liu, S, Wang, X, Wang, J & Zou, H 2017, 'Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia', Cancer Epidemiology Biomarkers and Prevention, vol. 26, no. 9, pp. 1411-1419. https://doi.org/10.1158/1055-9965.EPI-17-0153
Niu, Feng ; Wen, Jialing ; Fu, Xinhui ; Li, Chujun ; Zhao, Rongsong ; Wu, Shan ; Yu, Hao ; Liu, Xianglin ; Zhao, Xia ; Liu, Side ; Wang, Xinying ; Wang, Jianping ; Zou, Hongzhi. / Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 9. pp. 1411-1419.
@article{73057463db3e4add9e5640aed41c77e0,
title = "Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia",
abstract = "Background: Although the incidence of colorectal cancer is steadily increasing, screening for colorectal cancer with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. Syndecan-2 (SDC2) is frequently methylated in colorectal cancer. However, the value of a stool test of methylated SDC2 for the detection of colorectal cancer is unknown. Methods: Methylation status of SDC2 was tested in cell lines and 398 colorectal tissue samples and further evaluated with 497 stool samples, including 196 from colorectal cancer patients, 122 from adenoma patients, and 179 from normal individuals, using real-Time methylation-specific PCR. The impacts of one quantitative partial stool sampling device and 17 potentially interfering substances on the performance of fecal methylated SDC2 were also analyzed. SDC2 expression was also measured. Results: SDC2 methylation level was higher in 96.8{\%} (120/ 124) of colorectal cancer tissues compared with paired adjacent normal epithelia. Stool test of methylated SDC2 detected 81.1{\%} (159/196) of colorectal cancer and 58.2{\%} (71/122) of adenomas at a specificity of 93.3{\%} (167/179). No significant difference was found between partial and whole stool collection on colorectal cancer detection (P > 0.05, R2 = 0.80). Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2. SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia. Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms. Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.",
author = "Feng Niu and Jialing Wen and Xinhui Fu and Chujun Li and Rongsong Zhao and Shan Wu and Hao Yu and Xianglin Liu and Xia Zhao and Side Liu and Xinying Wang and Jianping Wang and Hongzhi Zou",
year = "2017",
month = "9",
day = "1",
doi = "10.1158/1055-9965.EPI-17-0153",
language = "English (US)",
volume = "26",
pages = "1411--1419",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia

AU - Niu, Feng

AU - Wen, Jialing

AU - Fu, Xinhui

AU - Li, Chujun

AU - Zhao, Rongsong

AU - Wu, Shan

AU - Yu, Hao

AU - Liu, Xianglin

AU - Zhao, Xia

AU - Liu, Side

AU - Wang, Xinying

AU - Wang, Jianping

AU - Zou, Hongzhi

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background: Although the incidence of colorectal cancer is steadily increasing, screening for colorectal cancer with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. Syndecan-2 (SDC2) is frequently methylated in colorectal cancer. However, the value of a stool test of methylated SDC2 for the detection of colorectal cancer is unknown. Methods: Methylation status of SDC2 was tested in cell lines and 398 colorectal tissue samples and further evaluated with 497 stool samples, including 196 from colorectal cancer patients, 122 from adenoma patients, and 179 from normal individuals, using real-Time methylation-specific PCR. The impacts of one quantitative partial stool sampling device and 17 potentially interfering substances on the performance of fecal methylated SDC2 were also analyzed. SDC2 expression was also measured. Results: SDC2 methylation level was higher in 96.8% (120/ 124) of colorectal cancer tissues compared with paired adjacent normal epithelia. Stool test of methylated SDC2 detected 81.1% (159/196) of colorectal cancer and 58.2% (71/122) of adenomas at a specificity of 93.3% (167/179). No significant difference was found between partial and whole stool collection on colorectal cancer detection (P > 0.05, R2 = 0.80). Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2. SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia. Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms. Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.

AB - Background: Although the incidence of colorectal cancer is steadily increasing, screening for colorectal cancer with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. Syndecan-2 (SDC2) is frequently methylated in colorectal cancer. However, the value of a stool test of methylated SDC2 for the detection of colorectal cancer is unknown. Methods: Methylation status of SDC2 was tested in cell lines and 398 colorectal tissue samples and further evaluated with 497 stool samples, including 196 from colorectal cancer patients, 122 from adenoma patients, and 179 from normal individuals, using real-Time methylation-specific PCR. The impacts of one quantitative partial stool sampling device and 17 potentially interfering substances on the performance of fecal methylated SDC2 were also analyzed. SDC2 expression was also measured. Results: SDC2 methylation level was higher in 96.8% (120/ 124) of colorectal cancer tissues compared with paired adjacent normal epithelia. Stool test of methylated SDC2 detected 81.1% (159/196) of colorectal cancer and 58.2% (71/122) of adenomas at a specificity of 93.3% (167/179). No significant difference was found between partial and whole stool collection on colorectal cancer detection (P > 0.05, R2 = 0.80). Among 17 interfering substances, only berberine at high concentrations inhibited fecal detection of methylated SDC2. SDC2 was overexpressed in colorectal cancer tissues compared with normal epithelia. Conclusions: Fecal methylated SDC2 is a valuable biomarker for the noninvasive detection of colorectal neoplasms. Impact: Stool DNA test of methylated SDC2 would serve as an alternative method for screening colorectal neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=85028937261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028937261&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-17-0153

DO - 10.1158/1055-9965.EPI-17-0153

M3 - Article

C2 - 28619831

AN - SCOPUS:85028937261

VL - 26

SP - 1411

EP - 1419

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -